

**FIRST AND ONLY
FDA-APPROVED**

oral medicine for children with pediatric low-grade glioma (pLGG) that returned or did not respond to treatment and who have a certain type of abnormal BRAF gene

A guide to discuss OJEMDA™ with your child's doctor



ojemda™
(tovorafenib)

100 mg tablets
25 mg/mL for oral suspension

THIS CHILD HAS A BRAIN TUMOR

Let's Talk OJEMDA

*Breslyn,
lives with pLGG*

INDICATION

What is OJEMDA™ (tovorafenib)?

OJEMDA is a prescription medicine used to treat certain types of brain tumors (cancers) called gliomas in patients 6 months and older:

- that is a pediatric low-grade glioma (LGG), **and**
- that has come back after previous treatment or has not responded to previous treatment **and**
- that has a certain type of abnormal "BRAF" gene.

IMPORTANT SAFETY INFORMATION

Before taking or giving OJEMDA, tell your healthcare provider about all of your or your child's medical conditions, including if you:

- have bleeding, skin, or liver problems
- are pregnant or plan to become pregnant. OJEMDA can harm your unborn baby.

Please see Important Safety Information on pages 4-5, and full [Patient Information](#), including Instructions for Use.

Starting the conversation

Knowledge is power.

Managing treatment for pLGG can get complicated. Being prepared for doctor appointments can help you get the information you need to make the right decision for your child.

Below are questions to help you start the discussion about OJEMDA.

- Could targeted therapy like OJEMDA be appropriate for my child?
- Why should we consider OJEMDA? What other options do we have?
- What are the results that have been seen with OJEMDA?
- How quickly will we know if the tumor is responding to OJEMDA?
- What side effects should we know about? Is there anything that we can do to manage them?
- How frequent would my child's follow-up visits be?
- How would my child take OJEMDA?
- If my child takes OJEMDA, how often would you recommend they get MRI and lab tests?
- What is the typical treatment timeline with OJEMDA?
- How can I learn more about OJEMDA?

Please see Important Safety Information on pages 4-5, and full [Patient Information](#), including Instructions for Use.

 **ojemda™**
(tovorafenib)
100 mg tablets
25 mg/mL for oral suspension

Important Safety Information

INDICATION

What is OJEMDA™ (tovorafenib)?

OJEMDA is a prescription medicine used to treat certain types of brain tumors (cancers) called gliomas in patients 6 months and older:

- that is a pediatric low-grade glioma (LGG), **and**
- that has come back after previous treatment or has not responded to previous treatment **and**
- that has a certain type of abnormal "BRAF" gene.

IMPORTANT SAFETY INFORMATION

Before taking or giving OJEMDA, tell your healthcare provider about all of your or your child's medical conditions, including if you:

- have bleeding, skin, or liver problems
- are pregnant or plan to become pregnant. OJEMDA can harm your unborn baby.

Females who are able to become pregnant:

- You should use effective non-hormonal birth control (contraception) during treatment with OJEMDA and for 28 days after your last dose of OJEMDA.

Males with female partners who are able to become pregnant should use effective non-hormonal birth control (contraception) during treatment with OJEMDA and for 2 weeks after your last dose of OJEMDA.

- are breastfeeding or plan to breastfeed. Do not breastfeed during treatment and for 2 weeks after your last dose of OJEMDA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What should I avoid while taking OJEMDA?

Limit the amount of time you spend in sunlight. OJEMDA can make your skin sensitive to the sun (photosensitivity). Use sun protection measures, such as sunscreen, sunglasses and wear protective clothes that cover your skin during your treatment with OJEMDA.

What are the possible side effects of OJEMDA?

OJEMDA may cause serious side effects, including:

- **bleeding problems (hemorrhage)** are common and can also be serious. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including:
 - headache, dizziness or feeling weak
 - coughing up blood or blood clots
 - vomiting blood or your vomit looks like "coffee grounds"
 - red or black stools that look like tar



Please see full [Patient Information](#), including **Instructions for Use**, for more information.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of OJEMDA? (cont'd)

OJEMDA may cause serious side effects, including: (cont'd)

- **skin reactions, including sensitivity to sunlight (photosensitivity).** OJEMDA can cause skin reactions that can become severe. Tell your healthcare provider if you get new or worsening skin reactions, including:
 - rash
 - bumps or tiny papules
 - acne
 - peeling, redness, or irritation
 - blisters
- **liver problems.** Your healthcare provider will do blood tests to check your liver function before and during treatment with OJEMDA. Tell your healthcare provider right away if you develop any of the following symptoms:
 - yellowing of your skin or your eyes
 - dark or brown (tea-colored) urine
 - nausea or vomiting
 - loss of appetite
 - tiredness
 - bruising
 - bleeding
 - pain in your upper right stomach area
- **slowed growth in children.** Growth will be checked routinely during treatment with OJEMDA.

The most common side effects of OJEMDA include:

- rash
- hair color changes
- tiredness
- viral infection
- vomiting
- headache
- fever
- dry skin
- constipation
- nausea
- acne
- upper respiratory tract infection

OJEMDA may cause fertility problems in males and females, which may affect your ability to have children.

These are not all the possible side effects of OJEMDA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full [Patient Information](#), including **Instructions for Use**, for more information.

 **ojemda**[™]
(tovorafenib)
100 mg tablets
25 mg/mL for oral suspension



Joseph, lives with pLGG

“Mutual trust between families and doctors is key when making impactful decisions regarding a child’s health. We are all on the team together.”

— Clare, caregiver of a child living with pLGG

Visit [OJEMDA.com](https://www.ojemda.com) to find out more and explore additional educational resources

Please see Important Safety Information on pages 4-5, and full [Patient Information](#), including Instructions for Use.

Day One, the Day One logo, OJEMDA, and the OJEMDA logo, are trademarks or registered trademarks of Day One Biopharmaceuticals, Inc.

©2024 Day One Biopharmaceuticals, Inc. All rights reserved.
TOVO-US-0062, 04/24 (v1.0).



ojemda™
(tovorafenib)

100 mg tablets
25 mg/mL for oral suspension